Skip to the content
Aresma PartnersAresma Partners
Corporate Finance and M&A Advisory Services
  • Approach
  • M&A and Financial Advisory
  • How
  • Contact us
  • Approach
  • M&A and Financial Advisory
  • How
  • Contact us

Author: AresmaPartner

RSS CSRwire Press Releases, Events and Reports

  • An error has occurred, which probably means the feed is down. Try again later.

RSS TechCrunch

  • Deel wants Rippling to hand over any agreements involving paying the alleged spy May 19, 2025
    Deel has lobbed a new volley in the ongoing legal battle with rival HR tech startup Rippling. Deel filed a motion, containing a series of letters, asking the Irish court to make Rippling hand over information. In one letter, Deel wants unredacted versions of witness affidavits, including the famed one by former Rippling employee, Keith […]
  • Uber eyes B2B logistics push in India through state-backed open commerce network May 19, 2025
    Uber is entering India’s growing B2B logistics market by extending its partnership with the Indian government-backed nonprofit that aims to break the domination of the e-commerce duo Amazon and Walmart-backed Flipkart and widen digital commerce in the South Asian nation. On Monday, the ride-hailing giant announced it will soon launch its B2B logistics service through […]

RSS VentureBeat

  • Foxconn builds AI factory in partnership with Taiwan and Nvidia May 19, 2025
    Nvidia and Foxconn announced they are working with the Taiwan government to build an AI factory supercomputer.

RSS Biotech Finances

  • Arecor Therapeutics, Massalia Therapeutics May 19, 2025
    (Royaume-Uni/Biotech/Obésité) – Arecor Therapeutics (AREC) collabore avec Skye Bioscience (SKYE) pour développer une nouvelle formulation concentrée de nimacimab, un anticorps monoclonal inhibiteur CB1, grâce à sa plateforme Arestat. Ce candidat est actuellement évalué dans une étude de phase IIa chez des patients obèses ou en surpoids, avec des résultats attendus fin T3 ou début T4 […]
  • MALADIE DE BATTEN : THERANEXUS CONFIRME SA STRATÉGIE May 16, 2025
    Theranexus et la Fondation Beyond Batten Disease dévoilent des données inédites en vie réelle démontrant une stabilisation de l’acuité visuelle chez des patients atteints de la maladie de Batten CLN3 traités par Batten-1. Une première qui conforte la stratégie clinique de la biotech française à l’approche de sa phase 3. Pour la première fois, un […]
Aresma Partners, 10/35 Howard St, Brisbane City QLD 4000, Australia Australia Contact - 594 a chemin du quartier d'Espagne, 30900 Nimes, Languedoc-Roussillon, Occitanie, France Contact France
To the top ↑ Up ↑
  • France
  • United Kingdom
  • Australia